NEW YORK (GenomeWeb) – Signal Genetics reported after the close of the market Wednesday that its fourth quarter revenues were essentially flat year over year.

For the three months ended Dec. 31, 2015, the company reported revenues of $659,000 compared to $655,000 in Q4 2014. Signal attributed the rise in revenues to an increase in testing volume for its MyPRS myeloma risk test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.